|Closed||Ovarian Cancer||Phase I||
This phase I trial is studying the side effects, good or bad, of vaccine therapy (IGFBP-2) in treating patients with stage III-IV ovarian cancer. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells.
- Patients with advanced stage ovarian cancer, stages III or IV, who have been treated to complete remission with standard therapies including primary debulking surgery
- Cancer antigen 125 (CA-125) level within normal limits for the testing laboratory must be documented 90 days prior to enrollment when the assessment of CA-125 is applicable
- Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy, prior to enrollment
- Patients must be at least 28 days post systemic steroids prior to enrollment
- Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status Score of =< 2
- Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
- Estimated life expectancy of more than 6 months
- White Blood Cell (WBC) >= 3000/mm^3
- Hemoglobin (Hgb) >= 10 mg/dl
- Hematocrit (Hct) >= 28%
- Serum creatinine =< 2.0 mg/dl or creatinine clearance > 60 ml/min
- Total bilirubin =< 2.5 mg/dl
- Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) =< 3 times upper limit of normal (ULN)
- Blood glucose < 1.5 ULN
- Patients must be at least 18 years of age.
- Patients with any of the following cardiac conditions: symptomatic restrictive cardiomyopathy; unstable angina within 4 months prior to enrollment; New York Heart Association functional class III-IV heart failure on active treatment; symptomatic pericardial effusion
- Uncontrolled diabetes
- Patients with any contraindication to receiving sargramostim (rhuGM-CSF) based products
- Ovarian cancer of a low malignant potential phenotype or clear cell histology
- Patients with any clinically significant autoimmune disease uncontrolled with treatment
- Patients who are currently receiving an anti-IGF-IR monoclonal antibody as part of their treatment regimen
- Patients who are simultaneously enrolled in any other treatment study
- All subjects able to bear children
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.